Results 41 to 50 of about 2,479 (207)

Gender aspects of CGRP in migraine [PDF]

, 2017
Background: Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood.
Labastida-Ramírez, A. (Alejandro), Maassen van den Brink, A. (Antoinette), Rubio-Beltrán, A.E. (Eloísa), Villalón, C.M. (Carlos)   +3 more
core   +2 more sources

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience [PDF]

, 2023
Background Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom.
Fitzek, Mira, Overeem, Lucas H., Raffaelli, Bianca, Reuter, Uwe, Storch, Elisabeth, Terhart, Maria   +5 more
core   +1 more source

Mode and site of action of therapies targeting CGRP signaling [PDF]

, 2023
Calcitonin; Headache; MigraineCalcitonina; Dolor de cabeza; MigrañaCalcitonina; Mal de cap; MigranyaTargeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that ...
Braniste, Diana, Caronna, Edoardo, Dapkute, Austeja, GOLLION, Cedric, Labastida Ramírez, Alejandro, Stanyer, Emily   +5 more
core   +4 more sources

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

The Journal of Headache and Pain, 2023
Background Monoclonal antibodies targeting the CGRP pathway are effective and safe for prophylactic treatment of episodic (EM) and chronic migraine (CM).
Andreas Straube, Gregor Broessner, Charly Gaul, Xenia Hamann, Joachim Hipp, Torsten Kraya, Lars Neeb   +6 more
doaj   +1 more source

A Comparison of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard Migraine Prophylaxis in Those with Episodic Migraines [PDF]

, 2023
Migraines are debilitating and a frequent reason for primary care visits. Migraines interfere with an individual’s work, school, and daily life.
Harms, Alexie
core   +4 more sources

Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies [PDF]

, 2023
Background and purpose: Anti-calcitonin gene-related peptide (CGRP) (receptor) antibodies effectively reduce overall migraine attack frequency, but whether there are differences in effect between perimenstrual and nonperimenstrual migraine days has not ...
de Vries Lentsch, Simone, le Cessie, Saskia, MaassenVanDenBrink, Antoinette, Terwindt, Gisela M., van der Arend, Britt W.H., Verhagen, Iris E.   +5 more
core   +3 more sources

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study [PDF]

, 2023
Background: To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple ...
Aguggia, Marco, Aurilia, Cinzia, Autunno, Massimo, Barbanti, Piero, Bonassi, Stefano, Carnevale, Antonio, Colombo, Bruno, d'Onofrio, Florindo, d'Onofrio, Luigi, Di Clemente, Laura, Egeo, Gabriella, Filippi, Massimo, Finocchi, Cinzia, Frediani, Fabio, Messina, Stefano, Proietti, Stefania, Ranieri, Angelo, Rao, Renata, Sette, Giuliano, Tasillo, Miriam, Tomino, Carlo, Torelli, Paola, Zoroddu, Francesco   +22 more
core   +1 more source

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

The Journal of Headache and Pain, 2022
Background Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults.
Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari   +10 more
doaj   +1 more source

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

Pharmaceutics, 2021
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor.
Aksana Jones, Orit Cohen-Barak, Andrijana Radivojevic, Jill Fiedler-Kelly   +3 more
doaj   +1 more source

Fremanezumab: First Global Approval [PDF]

Drugs, 2018
Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine).
openaire   +2 more sources